Many population-based retrospective and prospective studies have found that regular usage of selective cyclooxygenase-2 (COX-2) inhibitors such as MLX are connected to a lower incidence and mortality rate of CRC [14]. This evidence concerns the gene PTGS2 and colorectal carcinoma.